In a 34-year-old healthy woman with no prior cervical dysplasia and a normal Pap smear but a positive high-risk HPV test, what is the appropriate next step in management?

Management of Normal Pap Smear with Positive High-Risk HPV in a 34-Year-Old Woman

For a 34-year-old woman with a normal Pap smear but positive high-risk HPV test, repeat co-testing (both Pap and HPV) at 12 months is the preferred next step. 1

Algorithmic Approach to Management

Initial Management (At 12 Months)

• Repeat both cytology and HPV testing at 12 months 1
• This conservative approach is preferred because:
  • The majority (approximately 60%) of HPV-positive women become HPV-negative during follow-up 1
  • Immediate colposcopy would result in unnecessary procedures given the low immediate risk
  • The 12-month interval allows time for transient infections to clear

At the 12-Month Follow-Up Visit

If HPV remains positive:

• Proceed directly to colposcopy, regardless of cytology results 1

If both tests are negative:

• Return to routine screening in 3 years 1

If cytology shows any abnormality (ASC-US or worse):

• Refer to colposcopy per standard ASCCP guidelines 1

Role of HPV Genotyping (Optional Strategy)

While the standard approach is repeat testing at 12 months, HPV 16/18 genotyping can be considered as an alternative triage strategy if available 1:

If HPV 16 or 18 positive:

• Refer directly to colposcopy 2
• These genotypes carry substantially higher risk: 21% and 18% developed CIN3 over 10 years, compared to only 1.5% for other high-risk types 1

If positive for other high-risk HPV types (not 16/18):

• Follow standard protocol: repeat co-testing at 12 months 1

Important Clinical Considerations

Why Not Immediate Colposcopy?

The 2014 ASCCP consensus conference determined that the current risk for CIN3+ after a negative Pap with positive HPV is below the agreed threshold for immediate colposcopy 2. The risk increases sufficiently only with:

• Persistent HPV positivity at 12 months
• Presence of HPV 16 or 18 specifically
• Development of cytologic abnormalities

Common Pitfalls to Avoid

1. Do not perform cytology alone for follow-up - Co-testing (HPV + Pap) is superior to cytology alone for detecting missed disease 3

2. Do not use low-risk HPV testing - Only high-risk (oncogenic) HPV types should be tested 1

3. Do not extend follow-up beyond 12 months initially - While some older guidelines suggested longer intervals, updated data shows this population requires 12-month surveillance 2

4. Do not stop screening at age 65 if this result occurs near that age - HPV-negative results with prior abnormalities require continued surveillance 2

Special Consideration for HPV 16/18

If genotyping reveals HPV 16 or 18, immediate colposcopy is warranted because these genotypes increase the risk for CIN3 sufficiently to merit immediate evaluation, even with negative cytology 2. For HPV 18 specifically, endocervical sampling at colposcopy is acceptable given its association with adenocarcinoma 3.

Documentation and Follow-Up

Ensure robust systems for:

• Tracking the 12-month return visit
• Documenting all test results clearly
• Having protocols to locate patients who miss appointments 4

This risk-based approach balances the need to detect significant disease while avoiding overtreatment of transient infections that will spontaneously clear in the majority of cases.